The new office will give clients access to the company's services in the Chinese market.
PharmaLex Group, a provider of specialized services for the pharma, biotech, and medtech industries worldwide, has announced the opening of a new branch in Beijing, China, giving global clients access to a team of regulatory experts in the region.
As of September 2022, the newly established PharmaLex Beijing team, which includes personnel joining from Bayer China, will be offering pharmacovigilance, regulatory affairs, development consulting, and quality management to global clients bringing products to the China market. PharmaLex China will also be the local contact point for Chinese-based biopharmaceutical companies that are developing pharmaceuticals or medical devices with a goal of entering the European or US markets.
Continue reading here.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.